Bull & Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the entry multiple is the cheapest in CTEC's listed history with two genuinely defended franchises (180 Medical, Infusion Care) intact, but the next print decides whether the cash-conversion narrative survives a definitional reset. Bull and Bear largely agree on the facts; they disagree on whether FY25 was a transition-year reset or the start of a credibility unwind. The decisive tension is the margin glidepath, and the same August 2026 H1 release that Bull calls his primary catalyst is also Bear's primary trigger. With three months to a binary print, paying up before confirmation is undisciplined; ignoring 51% upside with two real moats and a falling share count is also undisciplined. Wait for the H1 2026 adjusted operating margin and DSO data before sizing.

Bull Case

Bull-case price scenario: 310p (~51% above 205.20p on 8 May 2026), built on 14.5x FY27E adjusted EBITDA of ~$700M (25% adj op margin × $2.8B revenue + ~$110M D&A) less ~$1.45B net debt, ÷ ~1,954M shares, at GBP/USD ~1.27. The multiple sits halfway between CTEC's 12-13x and Coloplast's 16.6x; consensus 303p anchors the range. Timeline: 12-18 months. Primary catalyst: August 2026 H1 results — adjusted operating margin print at ≥23% absorbing the full ~20 bps tariff load. Disconfirming signal: H1 2026 adj op margin under 22.5% with no clear path back, or year-end FY26 DSO remaining above 60 days without payables release reversing.

Bear Case

Bear-case price scenario: 165p (~$2.07/share equivalent), implying ~$4.0B equity vs ~$5.0B today. Method: Smith+Nephew compression at 12.2x EV/EBITDA on FY26E EBITDA of ~$500M (FY25 $540M minus ~$40M of FDA remediation, InnovaMatrix step-down, and tariff phasing) = $6.1B EV less $1,500M net debt = ~$4.6B equity / 1,954M shares. Triangulated against the financials bear case (11x EV/EBITDA, FCF flat = 167p) and the FY18 floor at ~146p. Timeline: 12 months. Primary trigger: August 2026 H1 — adj op margin below 22% (vs ≥23% guide) with the full tariff load and FDA remediation spend; the working-capital reversal lands in the same release. Cover signal: H1 2026 prints adj op margin ≥23.5% AND DSO normalised below 56 days AND FDA Warning Letter resolved without consent decree or import alert.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. The bull edges out the bear because two of CTEC's franchises — 180 Medical at 59% own-brand and Infusion Care with contracted OEM capacity — are visibly defended and roughly 40% of revenue, the entry multiple is the cheapest in the listed history, and $95M of mechanical amortisation roll-off narrows the IFRS-vs-adjusted wedge whether or not management lifts a finger. The single most important tension is the margin glidepath: a credible ≥23% H1 2026 print absorbing the full tariff load validates the FISBE-to-Accelerate flywheel, while anything sub-22% turns "closer to 24% by 2027" into the second walk-back. The bear could still be right because FY25 cash quality is genuinely propped up — a $121M growth-capex reclassification in a new CFO's first cycle, a $111M payables release, and a 25% receivables build all face a reversal test, and capital was levered out the door into the same year as the InnovaMatrix shock and the FDA Warning Letter. The condition that confirms the Lean Long is the August 2026 H1 release printing adjusted operating margin ≥23% with DSO trending below 60 and no FDA escalation; the condition that flips it to Avoid is H1 adj op margin sub-22% with DSO above 60 and AP unwinding. With three months to a binary print, the cost of waiting is small relative to the asymmetry of paying up before confirmation.